20 May 22
Recent developments pertaining to a highly anomalous outbreak of the rare disease “monkeypox” deserve our closest scrutiny while they give rise to extreme concern that the perpetual enterprise fraud construct of “COVID-19” is being rebooted with an interchangeable new impetus to replace the expiring effectiveness of SARS-CoV-2 and its progressive deterioration as a societal control mechanism.
Respective to the concept of the dual-purpose bird flu roll-out that I addressed in a recent article which draws back on earlier work, we must understand the utilitarian purpose that monkeypox provides. The important aspect of what I’m outlining here is that the virus or impetus being plugged into the enterprise fraud construct matters not whether it be bird flu, monkeypox or something different. What matters is that it is interchangeable in the sense of it being plugged in to drive the construct forward in designed perpetuity.
Read that as perpetual medical tyranny devised for societal control. From the psychological warfare perspective, it’s as simple as knowing that as soon as a population ceases fearing and reacting to one stimulus [SARS-CoV-2], another [or others] is introduced to elicit the same well-programmed response [bird flu and now monkeypox.] From the closing of a recent article,
Let’s close with COVID-19, enterprise fraud and medical tyranny. Therein, the earlier reported “Monkeypox” scare is being ushered-in as “SARS-CoV-2” expires in effectiveness as the impetus to continue medical tyranny in a construct of enterprise fraud. Another previously reported candidate for this is the bird flu. Whether it’s “monkeypox,” bird flu or something different matters not; rather it’s how either or both are used that matters. As I put it previously,
Respective to the above post on the stolen 2020 election: Rarely do “they” leverage a crisis for a singular purpose – far from it. Crises devised to sow fear and chaos are always multifaceted. COVID generally served to 1-steal an election, 2- install a proxy regime, 3-implement medical tyranny as the mechanism to implement the global plantation and 4-to attack the populace with multiple bioweapons [SARS-CoV-2 and the injections].
H5N1 “bird flu” will:
1-Replace COVID as the justification for continued medical tyranny
2-Serve as justification to slaughter chickens writ large
3-Exacerbate the planned and unfolding food shortage crisis
4-Serve as the rational for a new slate of mRNA injections
We’re in rinse/repeat mode now.Political Moonshine
Respective to the above quote and from the last article, I introduced the first report of monkeypox in the U.S. as follows:
It makes this headline highly disconcerting: US Confirms Monkeypox Virus In Massachusetts After UK, Spain, Portugal Cases In Men. From it, “A single case of the rare but serious monkeypox virus has been confirmed in Massachusetts in a man. Recent cases in the United Kingdom, Spain, and Portugal have been linked to men who have sex with other men.“
Does that sound like HIV? Absolutely it does. Don’t forget that SARS-CoV-2 has six artificial HIV insertions in its bioengineering. Moreover, the fact that is not being reported writ large is that evidence suggests that “monkeypox” is an illness of those who received the experimental COVID-19 mRNA injections.
What was unelected Anthony Fauci’s past specialty before becoming the nefarious and diminutive pocket tyrant? Answer: HIV.
What is the link to the recent outbreak of hepatitis among babies and young children respective to “vaccinated” mothers breastfeeding babies who haven’t received the mRNA injections? Answer: HIV.Political Moonshine
According to the CDC [emphasis added],
Monkeypox is a rare disease that is caused by infection with monkeypox virus. Monkeypox virus belongs to the Orthopoxvirus genus in the family Poxviridae. The Orthopoxvirus genus also includes variola virus (which causes smallpox), vaccinia virus (used in the smallpox vaccine), and cowpox virus.
Monkeypox was first discovered in 1958 when two outbreaks of a pox-like disease occurred in colonies of monkeys kept for research, hence the name ‘monkeypox.’ The first human case of monkeypox was recorded in 1970 in the Democratic Republic of the Congo (DRC) during a period of intensified effort to eliminate smallpox. Since then, monkeypox has been reported in people in several other central and western African countries: Cameroon, Central African Republic, Cote d’Ivoire, Democratic Republic of the Congo, Gabon, Liberia, Nigeria, Republic of the Congo, and Sierra Leone. The majority of infections are in Democratic Republic of the Congo.
Monkeypox cases in people have occurred outside of Africa linked to international travel or imported animals, including cases in the United States, as well as Israel, Singapore, and the United Kingdom.
The natural reservoir of monkeypox remains unknown. However, African rodents and non-human primates (like monkeys) may harbor the virus and infect people.CDC
Question: If monkeypox first emerged in humans during an effort to eliminate smallpox, which infers vaccinations, and the natural reservoir is unknown, how likely is it that monkeypox is another engineered virus perhaps deriving from smallpox vaccines or somehow correlated with them?
The CDC addresses monkeypox in the U.S. saying [emphasis added],
U.S. monkeypox cases are very rare. Monkeypox does not occur naturally in the United States, but cases have happened that were associated with international travel or importing animals from areas where the disease is more common.
Scientists at the Centers for Disease Control and Prevention (CDC) are collaborating with the Massachusetts Department of Public Health to investigate a situation in which a U.S. resident tested positive for monkeypox on May 18 after returning to the U.S. from Canada.
CDC is also tracking multiple clusters of monkeypox that have been reported in early- to mid-May in several countries that don’t normally report monkeypox, including in Europe and North America.
It’s not clear how people in those clusters were exposed to monkeypox but cases include people who self-identify as men who have sex with men. CDC is urging healthcare providers in the U.S. to be alert for patients who have rash illnesses consistent with monkeypox, regardless of whether they have travel or specific risk factors for monkeypox and regardless of gender or sexual orientation.CDC
Important in these developments is potential pretext that was established in November 2021 and earlier in July of the same year. From the CDC,
November 2021 Travel-Associated Case: The Centers for Disease Control and Prevention (CDC) and the Maryland Department of Health confirmedexternal icon on November 16, 2021 a case of monkeypox in a U.S. resident who recently returned from Nigeria to the United States. CDC is supporting state and local health officials, airline and travel industry partners, and other stakeholders to identify people who had possible contact with the patient. Because it can take up to 21 days for symptoms to develop after infection, contacts are being asked to monitor their health for that amount of time. CDC will continue to collaborate with partners to ensure the success of this investigation to help prevent additional cases of monkeypox in the United States.
July 2021 Travel-Associated Case: CDC and the Texas Department of State Health Services confirmed on July 15, 2021 a case of human monkeypox in a U.S. citizen who traveled from Nigeria to the United States on two commercial flights. CDC supported state and local health officials to identify more than 200 people who had possible contact with the patient. Contacts were asked to monitor their health for 21 days. In early September, 21 days had passed without additional cases identified, and the monitoring period for the remaining contacts ended. Strong collaboration between CDC, state and local health departments, airline and airport partners, and other stakeholders involved in this investigation helped to prevent additional cases of monkeypox in the U.S. related to this case.CDC
Going forward, recall that the exclusive body of work at Moonshine was first to evidence the enterprise fraud occurring at the unilateral emergency determinations processes in the “COVID-19 pandemic.” The fraudulently predicated emergency determinations – first a public health emergency declaration and then a pandemic declaration – permitted the issuance of Emergency Use Authorizations that circumvented regular constitutional governance altogether. That’s critical for what follows.
Recapitulating and respective to the U.S., we have pretext for monkeypox circa July and November of 2021 augmented by the new developments of a May 2022 outbreak. The CDC July and November monkeypox outbreaks noted above also coincided with financial maneuvering by a vaccine company – the only one to possess an FDA-approved vaccine for monkeypox – as evidenced below.
Now, according to the NY Post, and in ways that give rise to extreme concern, the WHO has convened an “emergency” meeting concerning the recent emergence of monkeypox in the U.S. and Europe,
The World Health Organization is reportedly convening an emergency meeting into the alarming spread of monkeypox around the world — including a possible case in the Big Apple.
The United Nations’ health authority is bringing together leading experts on the rare disease as a number of new countries announced their first confirmed cases Friday, according to The Telegraph.
The main concern is how the virus — usually concentrated in West Africa — may be spreading, the UK paper noted, with many of the new cases being with people who had not recently traveled.NY Post
Bearing a striking resemblance to the history of HIV and recalling Fauci’s deep involvement in it, the NY Post reports,
“Many of these global reports of monkeypox cases are occurring within sexual networks,” Inger Damon, director of CDC’s Division of High-Consequence Pathogens and Pathology, said.
However, the CDC stressed that the concerns should not be limited to gay men, stressing, “Those who have any sort of close personal contact with people with monkeypox could potentially also be at risk.”NY Post
Playing directly into the concept of enterprise fraud, there is only one known and approved vaccine for monkeypox and this is from the FDA’s website circa 24 Sep 19 [emphasis added]:
The U.S. Food and Drug Administration announced today the approval of Jynneos Smallpox and Monkeypox Vaccine, Live, Non-Replicating, for the prevention of smallpox and monkeypox disease in adults 18 years of age and older determined to be at high risk for smallpox or monkeypox infection. This is the only currently FDA-approved vaccine for the prevention of monkeypox disease.
Jynneos will be available for those determined to be at high risk of either smallpox or monkeypox infection. This vaccine is also part of the Strategic National Stockpile (SNS), the nation’s largest supply of potentially life-saving pharmaceuticals and medical supplies for use in a public health emergency that is severe enough to cause local supplies to be depleted. The availability of this vaccine in the SNS will help ensure that the vaccine is accessible in the U.S. if needed.
Jynneos does not contain the viruses that cause smallpox or monkeypox. It is made from a vaccinia virus, a virus that is closely related to, but less harmful than, variola or monkeypox viruses and can protect against both of these diseases. Jynneos contains a modified form of the vaccinia virus called Modified Vaccinia Ankara, which does not cause disease in humans and is non-replicating, meaning it cannot reproduce in human cells.
The effectiveness of Jynneos for the prevention of smallpox was determined in a clinical study comparing the immune responses in study participants who received either Jynneos or ACAM2000, an FDA-approved vaccine for the prevention of smallpox. The study included approximately 400 healthy adults, 18 through 42 years of age who had never been vaccinated for smallpox, in which half of the study participants received two doses of Jynneos administered 28 days apart, and half received one dose of ACAM2000. The group vaccinated with Jynneos had an immune response that was not inferior to immune responses to ACAM2000. Vaccine effectiveness for the prevention of smallpox was also inferred from supportive animal studies that showed prior vaccination with Jynneos protected non-human primates who were exposed to viruses related to the smallpox virus.
The effectiveness of Jynneos for the prevention of monkeypox disease is inferred from the antibody responses in the smallpox clinical study participants and from studies in non-human primates that showed protection of animals vaccinated with Jynneos who were exposed to the monkeypox virus.
The safety of Jynneos was assessed in more than 7,800 individuals who received at least one dose of the vaccine. The most commonly reported side effects were pain, redness, swelling, itching, firmness at the injection site, muscle pain, headache and fatigue. No safety concerns that would require a Medication Guide have been identified for Jynneos. Jynneos is administered in two doses given four weeks apart.
The FDA granted the approval of Jynneos to Bavarian Nordic A/S. The FDA granted the application Priority Review and with this approval, the FDA issued a material threat medical countermeasure (MCM) priority review voucher to Bavarian Nordic A/S. The Federal Food, Drug, and Cosmetic Act, as amended by the 21st Century Cures (Cures) Act, authorizes the FDA to award priority review vouchers to sponsors of approved material threat MCM product applications that meet certain criteria.FDA
Here, we latch onto Jynneos as produced by Bavarian Nordic A/S. As we do, we draw back on old Moonshine work thrusting BlackRock and Vanguard to the genesis of everything. The above graphic helps in succinct fashion right down to Alfa Bank, Durham and Sussmann and the Bidens, Rosemont Seneca and the linkage to Metabiota; the latter being the direct nexus to Ukraine and U.S. Department of Defense biolabs in the nation [a series of 45 recent articles evidence these positions all linked within the last one.]
Beginning with basics, consider the holders of Bavarian Nordic A/S according to Yahoo Finance:
Vanguard represents four of the top ten holders, which account for 8.92% of all shares; Vanguard holding 2.57% of that figure. This will bear down hard respective to holding percentages, voting rights and Invesco as evidenced below.
The timeline for Bavarian Nordic A/S is problematic for the reason that on 09 May 22, the company announced a shares buyback program to hedge incentive scheme obligations only two days after the 07 May 22 confirmation of the first European monkeypox case. The company has an evidenced history of this and from the company’s press release [emphasis added]:
COPENHAGEN, Denmark, May 9, 2022 – Bavarian Nordic A/S (OMX: BAVA) announced today the initiation of a new share buy-back program, under which the Company intends to buy back up to 71,562 of its own shares. The purpose of the share buy-back program is to meet the Company’s obligations arising from the share-based incentive programs for the Board of Directors and Executive Management, in accordance with the Company’s remuneration policy.
The share buy-back program is initiated pursuant to the authorization granted at the annual general meeting on April 5, 2022, according to which the Company may purchase up to 10 % of the Company’s share capital for the time being.
The share buy-back program will be executed in accordance with Regulation (EU) No. 596/2014 of the European Parliament and of the Council of 16 April 2014 on market abuse and supplementing Regulation (EU) 2016/1052 of 8 March 2016, which together constitute the Safe Harbour Regulation.
Bavarian Nordic A/S has appointed Danske Bank A/S Lead Manager of the program. Danske Bank A/S will buy back shares on behalf of Bavarian Nordic A/S and make decisions on trading with Bavarian Nordic A/S’ shares independently and without influence of Bavarian Nordic A/S.
The program will be implemented in accordance with the authorization within the following scope:
*A maximum of 71,562 shares will be purchased within the duration of the program.
*The maximum consideration for Bavarian Nordic A/S-shares purchased within the duration of the program is DKK 20 million. However, based on the closing price of Bavarian Nordic’s share on Nasdaq Copenhagen A/S on May 6, 2022, the total consideration is expected to be in the level of DKK 9.5 million.
*The program terminates at the latest on May 18, 2022.
*The maximum number of shares, which may be purchased per trading day, shall not exceed 25% of the average daily volume of shares in the Company traded on Nasdaq Copenhagen A/S in the preceding 20 trading days.
*The shares may not be purchased at a price which is higher than the higher of the following:
**The price of the last independent trade.
**The highest current independent purchase bid on Nasdaq Copenhagen A/S.
Bavarian Nordic A/S may terminate the program at any time. If the Company determines to terminate the program, the Company will give notice hereof.Bavarian Nordic A/S
Note from the above that Danske Bank A/S was appointed to oversee the program by Bavarian Nordic A/S. According to Yahoo Finance, here are the holders of Danske Bank A/S:
The company routinely appoints Danske Bank A/S to oversee its buyback programs functionally translating to Vanguard overseeing it as per shareholder percentages and voting rights. It holds 1.70% of the collective 4.03% and more than any other single holder.
Stock buyback programs present opportunities to “raise equity capital through the sale of common and preferred shares, it may seem counter-intuitive that a business might choose to give that money back. However, there are numerous reasons why it may be beneficial to a company to repurchase its shares, including ownership consolidation, undervaluation, and boosting its key financial ratios.“ They “can also be an easy way to make a business look more attractive to investors. By reducing the number of outstanding shares, a company’s earnings per share (EPS) ratio is automatically increased – because its annual earnings are now divided by a lower number of outstanding shares.” Additionally “In the event of a recession, share buybacks can be decreased more easily than dividends, with a far less negative impact on the stock price.” [SOURCE]
Coinciding with the announced stock buyback, we received the confirmation of the first monkeypox cases that were announced in Europe and the U.S. on 18 May 22 as reported and documented above; and with the first European case being reported to have occurred on 07 May 22; just two days before the shares buyback.
According to a Bavarian Nordic A/S press release,
The first European case was confirmed on May 7, 2022, in an individual who returned from a travel to Nigeria, where monkeypox is endemic. Subsequently, more than 20 cases have been confirmed across England, Portugal and Spain with additional suspected cases currently being investigated. Evidence points to that most of the infections have been acquired locally in these countries. In the US, a single case has been confirmed in a traveler from Canada, where no cases are yet confirmed, but several remain under investigation.Bavarian Nordic A/S
On the same date of 18 May 22, Bavarian Nordic A/S announced in a press release its transactions record in the shares buyback program; also terminating the program.
COPENHAGEN, Denmark, May 18, 2022 – Bavarian Nordic A/S (OMX: BAVA) announces that the share buy-back program, which was announced and initiated on May 9, 2022, has now been terminated, as the intended number of shares under the program has been repurchased. The program was executed in accordance with the provisions of Regulation (EU) No. 596/2014 of the European Parliament and of the Council of 16 April 2014 on market abuse and supplementing Regulation (EU) 2016/1052 of 8 March 2016, which together constitute the Safe Harbour Regulation. The purpose of the program was to meet the Company’s obligations arising from the share-based incentive program for the Board of Directors and Executive Management.
Under the program Bavarian Nordic A/S has bought back 71,562 shares, cf. the table below:Bavarian Nordic A/C
On the same day of 18 May 22 and according to a press release, Bavarian Nordic A/S secured a contract with the U.S government and BARDA – the well-evidenced entity in the Moonshine work into COVID-19 as a construct of enterprise fraud: “Bavarian Nordic to Manufacture First Freeze-dried Doses of Smallpox Vaccine upon Exercise of Contract Option by the U.S. Government.”
According to the company, the “USD 119 million option exercised for the manufacturing of freeze-dried JYNNEOS® in 2023 and 2024. This represents the first set of options with a total value of USD 299 million to convert the existing bulk vaccine, previously purchased by BARDA, to approximately 13 million freeze-dried JYNNEOS doses.”
Further and from the same,
“COPENHAGEN, Denmark, May 18, 2022 – Bavarian Nordic A/S (OMX: BAVA) announced today that the U.S. Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response at the U.S. Department of Health and Human Services, has exercised the first options under the contract to supply a freeze-dried version of JYNNEOS® smallpox vaccine, thus allowing for the first doses of this version to be manufactured and invoiced in 2023 and 2024.”Bavarian Nordic A/S
The next day on 19 May 22 and after Bavarian Nordic A/S had begun and terminated its shares buyback program in precise conjunction with the reported outbreaks of monkeypox, according to a company press release, it secured a vaccine order from an undisclosed European country.
COPENHAGEN, Denmark, May 19, 2022 – Bavarian Nordic A/S (OMX: BAVA) announced today that the Company has secured a contract with an undisclosed European country to supply its IMVANEX® smallpox vaccine in response to new cases of monkeypox evolving during May 2022.Bavarian Nordic A/S
Another shares purchase program makes the developments here more problematic and they build on information from an 09 Mar 21 press release indicating: 1-“The low end of the revenue range reflects a scenario where a lockdown due to COVID-19 continues beyond Q1 in key markets like the US and Germany. The higher end of the revenue range reflects a scenario where a gradual reopening will happen in key markets during Q2 and where travel starts picking up again in Q3 and Q4 of 2021.” and 2-“The smallpox and Ebola business are not expected to be impacted by COVID-19.”
Remember that respective to vaccination, smallpox and monkeypox are essentially one and the same.
On the same date of 09 Mar 21, Bavarian Nordic A/S announced: “Bavarian Nordic A/S Seeks to Strengthen its Capital Base and Commits to Ambitious Strategy on Promising COVID-19 Vaccine Candidate: COPENHAGEN, Denmark, March 9, 2021 – Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) (“Bavarian Nordic” or the“Company”) intends to raise new capital through an offering of new shares (the “New Shares”). Bavarian Nordic remains committed to the vision of creating one of the largest pure-play vaccine companies by 2025. The creation can be driven by organic as well as acquisitive growth; the latter of which was demonstrated through the acquisition of Rabipur/RabAvert and Encepur. Bavarian Nordic possesses leading capabilities within manufacturing, distribution and marketing of vaccines and believes that the developed know-how can now successfully be applied to the benefit of the battle against the COVID-19 pandemic.”
The company announced the completion of the directed issue the next day on 10 Mar 21: Bavarian Nordic A/S Announces Completion of Directed Issue and Private Placement of 5,150,000 New Ordinary Shares.
On 12 Mar 21, the company issued its financial statement for 2020 saying [emphasis added], “Strong execution and solid financial performance despite challenging markets: Paul Chaplin, President & Chief Executive Officer of Bavarian Nordic said: “We embarked on a commercial transition in 2020 with a strengthened product portfolio and a 2025 vision to grow Bavarian Nordic into one of the largest pure play vaccine companies, and saw strong execution in all areas supporting this vision. While our new markets in rabies and tick-borne encephalitis were challenged by the COVID-19 lock-down, we delivered results in line with or better than our original guidance, mostly due to our JYNNEOS business performing better than originally anticipated, by strong Encepur, Rabipur/RabAvert brand performance and by keeping a tight focus on profitability and cash.”
Relative to the holders of Bavarian Nordic A/S and respective to Vanguard and BlackRock as evidenced above, consider the following from another company press release; noting control of the company’s voting rights:
COPENHAGEN, Denmark, March 17, 2021 – Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) announces that the Company, as set out in Section 38 in the Danish Capital Markets Act and section 55, cf. 56 of the Danish Companies Act, has received notification from Invesco Ltd confirming that Invesco Ltd., as a result of Bavarian Nordic’s recent capital increase, indirectly holds below 5% of the voting rights in Bavarian Nordic A/S as of March 15, 2021.
The voting rights indirectly controlled by Invesco Ltd. are held by Invesco Advisers, Inc. to which voting right have been delegated by a number of funds managed by affiliates of the Invesco group management companies.Bavarian Nordic A/S
The institutional holders for Invesco are as follows and noting the prevalence of BlackRock and Vanguard:
Invesco’s Bavarian Nordic A/S voting rights are compounded by BlackRock and Vanguard. As previously noted, Vanguard represents four of the top ten holders of the company, which account for 8.92% of all shares; Vanguard holding 2.57% of that figure. Returning to the table above, Invesco’s holdings in the company [voting rights] tabulate 4.09%. With BlackRock and Vanguard being major institutional holders of Invesco, BlackRock and Vanguard control a chilling and hair-raising 6.66% of Bavarian Nordic A/S and thus have control over voting.
On 07 May 21, in a press release that when combined with the aforementioned U.S./BARDA contract becomes emblematic of stockpiling, the company announced smallpox and Jynneos contracts with the U.S government and BARDA – the well-evidenced entity in the Moonshine work into COVID-19 as a construct of enterprise fraud:
COPENHAGEN, Denmark, May 7, 2021 – Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) announced today that the U.S. Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response at the U.S. Department of Health and Human Services, has exercised the final USD 12 million option remaining under the USD 202 million order for JYNNEOS® (Smallpox and Monkeypox Vaccine, Live, Non-replicating) awarded in April 2020.
This option covers the supply of additional liquid-frozen JYNNEOS doses which will be manufactured in the Company’s new fill and finish facility during 2021. In addition, the total contract of USD 202 million for procurement includes manufacturing of bulk vaccine, which is revenue recognized in the years 2020-2022.
Paul Chaplin, President and CEO of Bavarian Nordic said: “Our contracts with BARDA have been foundational for the establishment of a sustainable manufacturing and supply of critical vaccines for protecting the United States of America. This year, we are launching operations in our newly established fill and finish plant, which enables us to bring the final step of commercial manufacturing of JYNNEOS in-house as the first product on the line, marking a significant milestone in our long-standing partnership with the U.S. government.”Bavarian Nordic A/S
On an 11 Jun 21 the company issued another press release directly related to monkeypox: “COPENHAGEN, Denmark, June 11, 2021 – Bavarian Nordic A/S (OMX: BAVA) announced today that the Company was recently engaged by Public Health England (PHE) and the Medicines and Health Products Regulatory Agency (MHRA) to supply its IMVANEX® smallpox vaccine in response to new cases of monkeypox in the UK. Two related cases were confirmed and admitted to a hospital.”
A 25 Aug 21 press release indicated the company’s general financial well-being for the first half of 2021: “So far this year, we also received new orders for our Ebola and smallpox vaccines and saw very important advancements in our pipeline assets with our promising COVID-19 vaccine candidate, ABNCoV2 entering Phase 2 after reporting highly promising clinical results.”
An 11 Nov 21 press release on the first nine months of 2021 indicated similar results: ““We continued to experience a challenging market environment for our travelers vaccine business during the third quarter, due to COVID-19. Despite these headwinds, we remain on track to meet our guidance as both our smallpox and Ebola vaccine sales remain unaffected.”
On 09 Dec 21, the company registered another increase in capital: “COPENHAGEN, Denmark, December 9, 2021 – Bavarian Nordic A/S (OMX: BAVA) (“Bavarian Nordic” or the “Company”) has in
connection with the directed issue and private placement today registered with the Danish Business Authority, a capital increase of a nominal value of DKK 63,736,800 (6,373,680 shares of DKK 10 each) (the “New Shares”), representing 9.94% of theregistered share capital prior to the capital increase (the “Offering”).”
On 19 Jan 22, the Bavarian Nordic A/S announced new leadership:
COPENHAGEN, Denmark, January 19, 2022 – Bavarian Nordic A/S (OMX: BAVA) announced today the appointment of Russell Thirsk as Executive Vice President and Chief Operating Officer, effective from April 1, 2022. Mr. Thirsk will take over this position from Henrik Birk, who has decided to seek new challenges outside Bavarian Nordic. The timing allows a period of handover from Henrik Birk to ensure a smooth transition.
Mr. Thirsk joins Bavarian Nordic from GSK, where he has served as Head of Operations at GSK Vaccines in Belgium since 2016, a role he assumed after GSK’s acquisition of Novartis’ vaccine business, where he served for more than two decades, holding leadership roles of increasing responsibility in vaccine manufacturing operations across various geographies. Mr. Thirsk holds a Master of Chemical Engineering from University of Nottingham.Bavarian Nordic A/S
GSK should strike a familiar tone with veteran Moonshiners because it draws back to old COVID-19 Moonshine and the very first articles exclusively written on COVID-19 as a construct of enterprise fraud drawing back to very early February 2020, “It’s the patent angles we’re tracking and these are the vectors: Gilead Sciences (holds the patent and goes back to GlaxoSmithKline), GSK (is a Rothschild’s owned corporation), Unitaid (NGO funded by George Soros and brokers patent-sharing deals), George Soros (funding Unitaid and the patent-sharing efforts in select African Nations while looking to penetrate China’s (and Brazil’s) closed markets for the same purpose.”
Also relevant to it all is Gilead’s entanglement with GlaxoSmithKline and of course, when looking at GSK, you must consider the Rothschilds’ ownership in GSK.
Here’s where that leaves us (from the same article),
We have a company in Gilead that intimately ties back to Harvard and the federal government and which specializes in anti-cancer and anti-viral medications; especially HIV. It also ties directly to biological weapons. Moreover, the company is losing patent protections while it simultaneously engaging in patent pools. It’s also working to develop new products while illegally fixing the prices of its current ones; while also lining their own pockets illegitimately. At the same time we also have Unitaid, funded by billionaire investor George Soros, working to expand Gilead’s patent pool operations in China, which just so happens to be experiencing a viral outbreak with 4 anomalous HIV insertions [later determined to be six]. An outbreak in China whereby a Washington State doctor just used Gilead’s drug Remdesivir to demonstrate the first likely effective treatment. All of this against the backdrop of Soros moving out of his entire Gilead position more than once.Political Moonshine
In the company’s 2021 annual report it indicated:
COPENHAGEN, Denmark, March 4, 2022 – Bavarian Nordic A/S (OMX: BAVA) today published its Annual Report for 2021. Below is a summary of the financial performance for the year and financial outlook for 2022. The financial performance was in line with, or better than, the latest guidance, issued on December 6, 2021. The full report is attached as a PDF file and can be found on the company’s website, www.bavarian-nordic.com.
Strong progress on strategic objectives – and a year of significant investments ahead to secure future growth!Bavarian Nordic A/S
Paul Chaplin, President & Chief Executive Officer of Bavarian Nordic said: “2021 was another eventful year where COVID-19 continued to make its mark on societies and on our business. The markets for Rabipur/RabAvert and Encepur remained affected by the low level of international travel and reduced access to physicians in key markets, whereas our smallpox and Ebola business were robust to the challenges set by the pandemic and enabled us to meet our financial targets for the year.
Relative to vaccination, smallpox is monkeypox per se and it’s good business – good enough to float them through the other half of their apparent involvement in enterprise fraud and the unintended consequences it delivers.
An 09 May 22 Bavarian Nordic A/S press release addressed the companies financial status as generally strong and especially as it relates to its COVID-19 vaccines and boosters, “Paul Chaplin, President & Chief Executive Officer of Bavarian Nordic said: “We have reported strong progress in our pipeline during the first quarter with additional Phase 2 results for our COVID-19 vaccine candidate, confirming its potential as a universal booster vaccine and we look forward to initiating the Phase 3 trial later this year.”
Through private equity manipulations, Bavarian Nordic A/S has been able to accomplish 5 apparent major priorities: 1-Remaining financially viable, 2-while engaging in COVID-19 vaccine and booster development, 3-while engaging in smallpox and monkeypox vaccine development, 4-to monopolize the entire monkeypox vaccine market, 5-while securing monkeypox vaccine contracts with the U.S./BARDA and an undisclosed European nation; with presumably more contracts forthcoming.
Once the obfuscating veneer of holding companies, shares percentages and voting rights are stripped away, we find the usual suspects front and center: Vanguard and BlackRock. This fact set is aggravated to extreme levels given the pretext being established relative to such a rare disease with limited transmission vectors compounded by the W.H.O. convening an emergency meeting over the matter.
The analysis distills it down to a reboot of the medical tyranny system implemented by the enterprise fraud construct people mistakenly call the “COVID-19 pandemic.” Altogether, it pushes us farther down the path to the global plantation.
If monkeypox progresses from the W.H.O. in incremental ways that see other member nations fall into alignment precisely as they did with COVID-19, we’ll know that the analysis is on the mark and moreover, we’ll know the hell we will come to face – again.
Given the deeply evidenced and heavy Nazi overtones threaded throughout COVID from start to present; and respective to lanes of clear eugenics found therein, do you not find it eerily odd that the name of this corporation is “Bavarian Nordic A/S,” which literally translates to “Germans with light skin and hair, and blue eyes?”